Last reviewed · How we verify
intraperitoneal nebulisation of magnesium sulphate
Magnesium sulphate delivered intraperitoneally reduces visceral pain and inflammation through local anti-inflammatory effects and modulation of nociceptive pathways.
Magnesium sulphate delivered intraperitoneally reduces visceral pain and inflammation through local anti-inflammatory effects and modulation of nociceptive pathways. Used for Postoperative visceral pain management, Prevention of peritoneal adhesions.
At a glance
| Generic name | intraperitoneal nebulisation of magnesium sulphate |
|---|---|
| Sponsor | B.P. Koirala Institute of Health Sciences |
| Drug class | Mineral supplement / Anti-inflammatory agent |
| Target | NMDA receptor (indirect antagonism); local anti-inflammatory pathways |
| Modality | Small molecule |
| Therapeutic area | Pain management / Perioperative care |
| Phase | FDA-approved |
Mechanism of action
Magnesium acts as a natural NMDA receptor antagonist and has anti-inflammatory properties when applied locally to peritoneal tissues. Intraperitoneal nebulisation delivers the agent directly to visceral structures, potentially reducing postoperative pain, adhesion formation, and inflammatory responses in the peritoneal cavity without systemic absorption.
Approved indications
- Postoperative visceral pain management
- Prevention of peritoneal adhesions
Common side effects
- Local peritoneal irritation
- Hypermagnesemia (if systemic absorption occurs)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: